LONDON (Alliance News) - N4 Pharma PLC shares were up on Wednesday after encouraging research on its Nuvec delivery system.
Shares in the pharma company were up 26% at 10.74 pence on Wednesday.
The Nuvec system stimulates the production of antibodies, proteins which are produced by the immune system in response to pathogens, and has potential for use in the creation of vaccines and cancer treatments.
Further analysis of N4 Pharma's most recent research found that strong levels antibodies were produced when using the Nuvec system, higher than the in vivo-jetPEI industry standard.
Moreover, results of the research showed that Nuvec produced a robust level of specific antibodies for both cancer treatments and viral vaccines.
"These results are once again another positive step forward for our Nuvec delivery platform. The data now shows Nuvec is capable of producing specific and relevant strong levels of antibodies required for the development of vaccines and cancer treatments," said N4 Pharma Chief Executive Nigel Theobald.
N4 Pharma Plc (N4P)